FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109492049> ?p ?o ?g. }

• W3109492049 abstract "Abstract Background XAPASS is a real-world, prospective, single-arm, observational study conducted as a post-marketing surveillance mandated by the health authority in Japan. Nowadays, direct oral anticoagulant therapy using factor Xa or thrombin inhibitor has been the standard of care for patients with non-valvular atrial fibrillation (NVAF) to prevent ischemic stroke. However, the clinical impact of reduced dosage (approved dose of 15 or 10 mg once daily in Japan is relatively reduced compared to global dosage) factor Xa inhibitor rivaroxaban in high-risk patients remains unclear. Purpose The present sub-analysis of XAPASS was carried out to assess long-term safety and effectiveness of reduced-dose rivaroxaban in high-risk NVAF patients for bleeding and thromboembolism. Methods All patients with NVAF who were newly started on rivaroxaban were eligible for surveillance. The principal safety outcome was a composite of major and non-major bleeding events, and the primary effectiveness outcome was a composite of ischaemic stroke, haemorrhagic stroke, non-central nervous system systemic embolism (non-CNS SE), and myocardial infarction (MI). In this present sub-analysis, high-risk patients were defined as those who had two of the following three risk factors: elderly (≥75 years old), low body weight (≤50 kg), and renal impairment (CrCl &lt;50 mL/min). Results In total, 11,308 patients were enrolled between April 2012 and June 2014 from 1,419 hospitals, and overall data were analysed from 10,664 patients from whom data were collected. Among them, 3,694 patients matched the criteria for the high-risk patients defined in this sub-analysis, and 6,970 patients did not match the criteria (non-high-risk patients). The mean treatment duration was 791±673 days in the high-risk patients and 944±709 days in the non-high-risk patients. Mean patient age was 80.9±5.5 years and 69.0±9.0 years at baseline, respectively. Mean CHADS2 score was 2.8 and 1.8, and CHA2DS2-VASc score was 4.4 and 2.9, respectively. The rates of CHADS2 component comorbidities were lower in the non-high-risk patients except for diabetes mellitus. The incidence rates of any bleeding, major bleeding, and the primary effectiveness outcomes were 4.8, 1.6, and 2.1%/patient-year in the high-risk patients. The incidence rates of these clinical events in the non-high-risk patients were 3.3, 0.9, and 1.0%/patient-year, respectively. Conclusions Incidence rates of long-term bleeding and thromboembolism were higher in the high-risk patients than in the non-high-risk patients. However, the rates of these outcomes using the Japan-specific reduced dose were not so high. Furthermore, the balance between safety and effectiveness outcomes was within an acceptable range. The present study provides useful information for physicians to stratify high-risk patients using the reduced dose in daily clinical practice. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): Bayer Yakuhin Ltd." @default.
• W3109492049 created "2020-12-07" @default.
• W3109492049 creator A5011996744 @default.
• W3109492049 creator A5012525365 @default.
• W3109492049 creator A5015204894 @default.
• W3109492049 creator A5024383318 @default.
• W3109492049 creator A5031249539 @default.
• W3109492049 creator A5042534277 @default.
• W3109492049 creator A5046989382 @default.
• W3109492049 creator A5055980263 @default.
• W3109492049 creator A5063280635 @default.
• W3109492049 creator A5066866386 @default.
• W3109492049 creator A5067341497 @default.
• W3109492049 creator A5079975386 @default.
• W3109492049 creator A5081443425 @default.
• W3109492049 creator A5087442638 @default.
• W3109492049 date "2020-11-01" @default.
• W3109492049 modified "2023-09-26" @default.
• W3109492049 title "Long-term outcomes of Japan-specific dosage of rivaroxaban in high-risk patients with non-valvular atrial fibrillation: analysis from the XAPASS" @default.
• W3109492049 doi "https://doi.org/10.1093/ehjci/ehaa946.0646" @default.
• W3109492049 hasPublicationYear "2020" @default.
• W3109492049 type Work @default.
• W3109492049 sameAs 3109492049 @default.
• W3109492049 citedByCount "0" @default.
• W3109492049 crossrefType "journal-article" @default.
• W3109492049 hasAuthorship W3109492049A5011996744 @default.
• W3109492049 hasAuthorship W3109492049A5012525365 @default.
• W3109492049 hasAuthorship W3109492049A5015204894 @default.
• W3109492049 hasAuthorship W3109492049A5024383318 @default.
• W3109492049 hasAuthorship W3109492049A5031249539 @default.
• W3109492049 hasAuthorship W3109492049A5042534277 @default.
• W3109492049 hasAuthorship W3109492049A5046989382 @default.
• W3109492049 hasAuthorship W3109492049A5055980263 @default.
• W3109492049 hasAuthorship W3109492049A5063280635 @default.
• W3109492049 hasAuthorship W3109492049A5066866386 @default.
• W3109492049 hasAuthorship W3109492049A5067341497 @default.
• W3109492049 hasAuthorship W3109492049A5079975386 @default.
• W3109492049 hasAuthorship W3109492049A5081443425 @default.
• W3109492049 hasAuthorship W3109492049A5087442638 @default.
• W3109492049 hasConcept C126322002 @default.
• W3109492049 hasConcept C127413603 @default.
• W3109492049 hasConcept C23131810 @default.
• W3109492049 hasConcept C2776301958 @default.
• W3109492049 hasConcept C2778661090 @default.
• W3109492049 hasConcept C2779161974 @default.
• W3109492049 hasConcept C2780645631 @default.
• W3109492049 hasConcept C500558357 @default.
• W3109492049 hasConcept C50440223 @default.
• W3109492049 hasConcept C71924100 @default.
• W3109492049 hasConcept C78519656 @default.
• W3109492049 hasConceptScore W3109492049C126322002 @default.
• W3109492049 hasConceptScore W3109492049C127413603 @default.
• W3109492049 hasConceptScore W3109492049C23131810 @default.
• W3109492049 hasConceptScore W3109492049C2776301958 @default.
• W3109492049 hasConceptScore W3109492049C2778661090 @default.
• W3109492049 hasConceptScore W3109492049C2779161974 @default.
• W3109492049 hasConceptScore W3109492049C2780645631 @default.
• W3109492049 hasConceptScore W3109492049C500558357 @default.
• W3109492049 hasConceptScore W3109492049C50440223 @default.
• W3109492049 hasConceptScore W3109492049C71924100 @default.
• W3109492049 hasConceptScore W3109492049C78519656 @default.
• W3109492049 hasLocation W31094920491 @default.
• W3109492049 hasOpenAccess W3109492049 @default.
• W3109492049 hasPrimaryLocation W31094920491 @default.
• W3109492049 hasRelatedWork W10296644 @default.
• W3109492049 hasRelatedWork W10367265 @default.
• W3109492049 hasRelatedWork W16735619 @default.
• W3109492049 hasRelatedWork W19155525 @default.
• W3109492049 hasRelatedWork W3370658 @default.
• W3109492049 hasRelatedWork W3388698 @default.
• W3109492049 hasRelatedWork W4844954 @default.
• W3109492049 hasRelatedWork W5696161 @default.
• W3109492049 hasRelatedWork W6528303 @default.
• W3109492049 hasRelatedWork W7954022 @default.
• W3109492049 isParatext "false" @default.
• W3109492049 isRetracted "false" @default.
• W3109492049 magId "3109492049" @default.
• W3109492049 workType "article" @default.